
Aveanna (AVAH) Upgraded to Strong Buy: What Does It Mean for the Stock?
Aveanna (AVAH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Loading news...

Aveanna (AVAH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

BAYRY, DAKT, ZTO, LRLCY and AVAH have been added to the Zacks Rank #1 (Strong Buy) List on January 21, 2026.

Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH - Get Free Report) has received a consensus rating of "Hold" from the eleven research firms that are currently covering the stock, MarketBeat.com reports. Six equities research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12-month target

Aveanna Healthcare Holdings Inc. (AVAH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

ATLANTA, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, today announced updated full year guidance for fiscal year 2025 (year ended January 3, 2026) and its initial full year guidance for fiscal year 2026 (year ending January 2, 2027).

Aveanna Healthcare (NASDAQ: AVAH - Get Free Report) and Elanco Animal Health (NYSE: ELAN - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability and institutional ownership. Analyst Ratings This is a breakdown of

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

This home-based care provider reported notable insider selling as its shares marked strong gains over the past year.

Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH - Get Free Report) CFO Matthew Buckhalter sold 17,289 shares of Aveanna Healthcare stock in a transaction dated Wednesday, December 31st. The shares were sold at an average price of $8.18, for a total transaction of $141,424.02. Following the completion of the sale, the chief financial officer directly owned 455,320

Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH - Get Free Report) insider Edwin Reisz sold 17,613 shares of the stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $7.85, for a total value of $138,262.05. Following the completion of the transaction, the insider owned 1,321,114 shares in

Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH - Get Free Report) CFO Matthew Buckhalter sold 18,340 shares of the firm's stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $7.85, for a total transaction of $143,969.00. Following the completion of the transaction, the chief financial officer directly owned 436,980

Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH - Get Free Report) CFO Matthew Buckhalter sold 17,448 shares of the company's stock in a transaction dated Tuesday, December 30th. The shares were sold at an average price of $8.36, for a total transaction of $145,865.28. Following the transaction, the chief financial officer owned 472,609 shares in the company,

Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH - Get Free Report) insider Edwin Reisz sold 16,755 shares of Aveanna Healthcare stock in a transaction on Tuesday, December 30th. The stock was sold at an average price of $8.36, for a total transaction of $140,071.80. Following the completion of the sale, the insider owned 1,355,329 shares of the

Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH - Get Free Report) insider Edwin Reisz sold 16,602 shares of the company's stock in a transaction dated Wednesday, December 31st. The shares were sold at an average price of $8.18, for a total value of $135,804.36. Following the completion of the sale, the insider owned 1,338,727 shares of the

Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH - Get Free Report) CEO Jeff Shaner sold 27,674 shares of the company's stock in a transaction dated Wednesday, December 31st. The stock was sold at an average price of $8.18, for a total value of $226,373.32. Following the completion of the transaction, the chief executive officer owned 2,423,536 shares

Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH - Get Free Report) CEO Jeff Shaner sold 29,357 shares of Aveanna Healthcare stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $7.85, for a total transaction of $230,452.45. Following the sale, the chief executive officer owned 2,394,179 shares in the company,

Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH - Get Free Report) CEO Jeff Shaner sold 27,929 shares of Aveanna Healthcare stock in a transaction on Tuesday, December 30th. The stock was sold at an average price of $8.36, for a total transaction of $233,486.44. Following the sale, the chief executive officer directly owned 2,451,210 shares of the

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Does Aveanna Healthcare (AVAH) have what it takes to be a top stock pick for momentum investors? Let's find out.

Aveanna (AVAH) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.